Ionis Pharmaceuticals Market Research Report
Company Overview
- Name: Ionis Pharmaceuticals, Inc.
- Mission of the Company: Ionis focuses on the discovery, development, and delivery of life-transforming genetic medicines, particularly those that target the root causes of diseases, to provide hope for patients.
- Founded: 1989
- Key People:
- Brett P. Monia, Ph.D., Chief Executive Officer
- Elizabeth L. Hougen, Executive Vice President, Chief Financial Officer
- C. Frank Bennett, Ph.D., Executive Vice President, Chief Scientific Officer
- Kyle Jenne, Executive Vice President, Chief Global Product Strategy Officer
- Joseph T. Baroldi, Executive Vice President, Chief Business Officer
- Richard S. Geary, Ph.D., Executive Vice President, Chief Development Officer
- Patrick R. O’Neil, Esq., Chief Legal Officer and General Counsel
- Eric E. Swayze, Ph.D., Executive Vice President, Research
- Eugene Schneider, M.D., Executive Vice President, Chief Clinical Development and Operations Officer
- Brian Birchler, Executive Vice President, Corporate and Development Operations
- Headquarters: No information is available
- Number of Employees: No information is available
- Revenue: No financial information is available from the data provided.
- What the Company is Known For: Ionis is a leader in RNA-targeted therapeutics, pioneering antisense technology to develop genetic medicines for a wide range of diseases.
Products
- Product Overview:
- WAINZUA (eplontersen): Designed for the treatment of polyneuropathy associated with hereditary transthyretin-mediated amyloidosis.
- TEGSEDI™ (inotersen) and WAYLIVRA® (volanesorsen): Commercialized through Akcea Therapeutics, Ionis's wholly-owned subsidiary.
- Pipeline: Includes over 40 first-in-class and/or best-in-class medicines designed to treat a broad range of diseases including neurological, cardiovascular, and rare diseases.
- High-Level Description and Key Features:
- Antisense Technology: Ionis’s proprietary platform targets RNA to prevent the production of proteins that cause disease—this innovative approach can either decrease the production of disease-causing proteins or increase the production of therapeutic proteins.
- Neurological Medicines: Targeting diseases such as Alexander Disease, Amyotrophic Lateral Sclerosis, Alzheimer’s, and Parkinson’s.
- Cardiovascular Medicines: Include treatments like Eplontersen for transthyretin-mediated amyloid cardiomyopathy and Olezarsen for severe hypertriglyceridemia.
- Specialty and Rare Medicines: Includes treatments for hereditary angioedema and metabolic disorders.
Recent Developments
- Recent Product Developments:
- WAINZUA (eplontersen) was recommended for approval by the EU’s CHMP for the treatment of polyneuropathy associated with hereditary transthyretin-mediated amyloidosis.
- New Product Data: Positive data for donidalorsen was presented at the ACAAI Annual Scientific Meeting.
- Regulatory Highlights:
- Zilganersen was granted U.S. FDA Fast Track designation for Alexander disease.
- Financial Activities:
- Conducted public offerings with Ionis announcing a $500.3 million public offering.
- Pipeline Expansion:
- Continuous innovation with antisense technology, focusing on precise and potent therapeutic solutions.
- Strategic Emphasis:
- Commitment to RNA-targeted medicines, emphasizing advances in drug discovery for unmet clinical needs in neurology and cardiometabolic diseases.
- Corporate Responsibility:
- Ionis emphasizes operating responsibly and sustainably, focusing on corporate responsibility pillars aimed at improving lives through innovation, empowering people and communities, and operating sustainably.
©1989 – 2024 Ionis Pharmaceuticals® is a registered trademark of Ionis Pharmaceuticals, Inc. Akcea Therapeutics® is a wholly owned subsidiary of Ionis Pharmaceuticals, Inc.
